Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Chengdu Suncadia Medicine obtained marketing approval for its Licancopan Fumarate Capsules from China's National Medical Products Administration.
The approved indication is for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy, according to a Thursday bourse filing.